DISCLAIMER: This page is intended for members of the general public in Finland only.
The information provided on this site is intended for general information and education for Finland-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Important information
For more information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), download the Package Leaflet.
Report an Adverse Event (AE)
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Finland.
Finnish
www-sivusto: www.fimea.fi
Lääkealan turvallisuus- ja kehittämiskeskus Fimea
Lääkkeiden haittavaikutusrekisteri
PL 55
00034 FIMEA
Swedish
webbplats: www.fimea.fi
Säkerhets- och utvecklingscentret för läkemedelsområdet Fimea
Biverkningsregistret
PB 55
00034 FIMEA
Contact Us
Tel: +358 09 42451062
09:00 - 17:00
Monday - Friday